Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy | Synapse
March 3, 2026Open Access
Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy
Key Points
Survival rates do not significantly improve with intermediate dose escalation of radiotherapy.
Patients receiving immunotherapy more than six weeks post-treatment showed consistent outcomes without dose changes.
Assessment involves analyzing patient survival in relation to radiotherapy and immunotherapy administration timelines.
Findings suggest that dose adjustments may not be necessary, highlighting treatment consistency.
Abstract
IDE of RT is not needed for patients diagnosed with stage III unresectable NSCLC who receive immunotherapy > six weeks after dcCRT.